$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| ASTRAZENECA:HIGH LEVEL RESULTS OF THE ARCTIC TRIAL | 24 Apr 2018 |
| FDA APPROVES TAGRISSO FOR 1ST-LINE USE IN NSCLC | 19 Apr 2018 |
| 6-K | 13 Apr 2018 |
| NOTICE OF AGM | 13 Apr 2018 |
| DIRECTORATE CHANGE | 05 Apr 2018 |
| AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU | 03 Apr 2018 |
| TOTAL VOTING RIGHTS | 03 Apr 2018 |
| FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA | 03 Apr 2018 |
| DIRECTOR/PDMR SHAREHOLDING | 28 Mar 2018 |
| DIRECTOR/PDMR SHAREHOLDING | 26 Mar 2018 |
| LOKELMA APPROVED IN THE EU | 22 Mar 2018 |
| ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE | 12 Mar 2018 |
| FILING OF FORM 20-F WITH SEC | 07 Mar 2018 |
| ANNUAL FINANCIAL REPORT | 06 Mar 2018 |
| TOTAL VOTING RIGHTS | 01 Mar 2018 |
| LYNPARZA CHMP FOR OVARIAN CANCER MAINTAINANCE | 23 Feb 2018 |
| ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLC | 20 Feb 2018 |
| SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS | 15 Feb 2018 |
| DIRECTOR/PDMR SHAREHOLDING | 05 Feb 2018 |
| AZN: FULL-YEAR 2017 RESULTS | 02 Feb 2018 |
